ATMI has completed a two-year, multi-million dollar expansion project for its Bloomington, Minnesota manufacturing facility. With this achievement, the company establishes its North American hub for the production, marketing, and development of its Integrity single-use technologies for biopharmaceutical and other life science applications.
Expansion of the Bloomington site, which will continue to host ATMI’s manufacturing operations for high-purity liners and specialty chemical dispense systems for the semiconductor and flat panel display industries, was unveiled.
The added capabilities double the company’s worldwide capacity for the fabrication of ATMI(R) LifeSciences’ Integrity product line of 2-D and 3-D transfer, storage, mixing, and bioreactor vessels, while adding supply chain contingency through a dual-manufacturing capability shared with the existing bioprocess manufacturing plant in Hoegaarden, Belgium.
Additional space remains that would double the production capacity to meet increasing demand.
ATMI CEO and president Doug Neugold sad that they have developed this facility in direct response to the growing needs of the North American customers for additional single-use bioprocess vessel manufacturing capacity.
“Creating a copy-exact of our Belgian facility for change management and supply chain security reasons also helped us to quickly replicate cGMP procedures. With advanced vessel design, 100% integrity testing, and extensive quality controls, we continue to apply our experience in semiconductor manufacturing to our life science business,” Neugold concluded.
ATMI LifeSciences senior vice president and general manager Mario Philips said that this expansion addresses the increasing demands of the biopharmaceutical marketplace for single-use vessels applications in the field of storage, mixing and bioreactors.